CUHK develops a novel magnetic helical microrobot with endoscope

Date: 
2022-10-27
Thumbnail: 
Body: 
CUHK develops a novel magnetic helical microrobot with endoscope-assisted delivery for biofilm eradication in ear tubes
 
Otitis media is an inflammation or infection located in the middle ear. It is a health problem commonly seen in children, usually caused by upper respiratory infections or bacterial infections. Some patients with fluid build-up, or effusion, need to the undergo the surgical procedure of, inserting a tympanostomy tube (also known as an ear tube or T-tube) in the tympanic membrane to drain the middle ear fluid, alleviating the effusion and pressure in the middle ear. However, bacterial biofilm may form in the ear tube over time and contribute to blockages and recurring infections.
 
CUHK’s cross disciplinary research team developed a magnetic helical microrobot with endoscope-assisted delivery for biofilm eradication in ear tubes. The novel treatment procedure has been validated in a human cadaver ex vivo, which is a promising sign for clinical application. Study results have been published in the international journal Science Advances.
 
Bacterial biofilms contribute to recurring infections, but eradication is difficult in the tortuous and obstructed auditory canals
 
About 7% of children under the age of six have had otitis media with effusion. The fluid may resolve on its own within a few weeks but if the condition prevails, surgical treatment becomes necessary. Insertion of an ear tube into the tympanic membrane is a procedure to treat otitis media with effusion. In Hong Kong, it is common for adult or child patients to undergo implant of ear tube for otitis media with effusion.
 
Biofilm builds up in the ear tube over time and contributes to otorrhea, or drainage of fluid from the ear, and debris deposition, which in turn can cause blockages and recurring infections. For severely blocked ear tubes, surgeons have to use specialised mechanical tools to clear the occlusion or replace the ear tube during endoscopy. This manoeuvre requires delicate expert skills to avoid injuries to the ossicular chain and tympanic membrane.  
 
Dr Chang Wai-tsz, Assistant Professor in the Department of Otorhinolaryngology, Head and Neck Surgery at CU Medicine explained, “Recurrent infections of ear refractory to antibiotic treatment and occlusion of the ear tube are the complications related to biofilms after operation. Antibiotics are usually used to prevent biofilm occlusion after surgery, but they cannot prevent infection in the long term, and may lead to antimicrobial resistance. Some patients who suffer from ear tube occlusion require frequent tube replacement, which increases their physical and financial burden.”  
 
Helical microrobots have chemical and mechanical effects in eradicating biofilm 
 
Hence, a research team with members from the Department of Mechanical and Automation Engineering at Faculty of Engineering, and the Department of Otorhinolaryngology, Head and Neck Surgery at CU Medicine joined hands to develop a magnetic helical microrobot with endoscope-assisted delivery for biofilm eradication in ear tube. The treatment system consists of helical microrobot, endoscope, magnetic actuation unit with robotic arm, and catheter. Surgeons first use an endoscope to deliver the helical microrobot with a catheter into the ear tube. Then they can remotely actuate the microrobot by the programmed magnetic field in the ear tube to perform biofilm eradication.      
 
Professor Zhang Li from the Department of Mechanical and Automation Engineering said, “During my post-doctoral studies at ETH Zurich in Switzerland, I was inspired by the flagellar movement (the locomotion of the tiny hairline appendages found on many plants) to develop helical microrobot. I further investigated the use of magnetic force for better motion control and applied it in the field of medical science. We learned from our counterparts in medicine about the challenge of treating recurrent infections from biofilm formation in ear tubes. From there, we developed helical microrobot that can promote a catalytic reaction to produce diffusion of reactive oxygen species and kill bacteria cells. So the microrobots have both chemical and mechanical methods of eradicating biofilm. The precision movement of the microrobot enables it to perform tasks harmlessly in a confined space with high accuracy, while inducing no pain.”
 
Dr Jason Chan Ying-kuen, Associate Professor in the Department of Otorhinolaryngology, Head and Neck Surgery at CU Medicine said, “The novel treatment procedure has been validated in a human cadaver ex vivo, which is a promising sign for clinical application. The invention can provide a more manageable alternative to the current treatment and alleviate the physical and psychological pressure from repetitive ear tube replacement. Next, we need to acquire more evidence about the safety and stability of the system to promote clinical application.”
 
Professor Joseph Sung, Dean of Lee Kong Chian School of Medicine and CUHK’s Emeritus Professor, said, “Although biofilm has been known for quite some time, the clearance of biofilm has been an unsolved problem for decades. So far, no medication has proven to be useful in clearing the microbes once they are established on the surface as a layer. This study represents a major breakthrough using both mechanical and chemical methods in the same modalities. Its application is not limited to ear tubes for otitis media: potentially it can be used in other medical devices or implants placed in the human body where biofilm infections can occur.”
 
This study was supported by Research Grants Council, Innovation and Technology Commission, Chow Yuk Ho Technology Centre for Innovative Medicine, CUHK T Stone Robotics Institute, Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences (CAS) – CUHK Joint Laboratory of Robotics and Intelligent Systems, and Multi-scale Medical Robotics Center under InnoHK.
 
(extracted from the press release issued on 27 Oct 2022 by CUHK Communications and Public Relations Office)

CUHK’s cross disciplinary research team developed a magnetic helical microrobot with endoscope-assisted delivery for biofilm eradication in ear tubes.(From left) Assistant Professor Dr Chang Wai-tsz and Associate Professor Dr Jason Chan from the Department of Otorhinolaryngology, Head and Neck Surgery at CU Medicine; and Professor Zhang Li from the Department of Mechanical and Automation Engineering.

Professor Zhang Li says biofilm has been known for quite some time. Research team will continue to explore the application of this novel system in other medical devices or implants placed in the human body where biofilm infections can occur.

This photo shows the novel system magnetic helical microrobot with endoscope-assisted delivery for biofilm eradication in ear tubes.

 

Filter: Dept: 
Faculty
MAE
Media Release

中大研發機械人治療中耳炎患者

中大跨學科研究團隊研發用磁力驅動的「磁控螺旋微機械人」,能在中耳導管中快速旋轉,刮除菌膜,再產生活性氧化物質殺菌。
 
中大指,中耳炎患者需要在耳膜置入導管,以抽出積水,積水長期累積,容易形成細菌菌膜,患者以往要經常更換導管,並使用抗生素的滴耳藥水,新技術能簡化治療程序,已在人體標本上做試驗,效果理想,希望五年內可以臨床使用。
Date: 
Thursday, October 27, 2022
Media: 
now TV

中大開發磁控螺旋微機械人 助治療中耳導管菌膜感染

中耳炎是常見的小兒感染,不少兒童因此出現中耳積水,嚴重更要使用中耳導管置入手術治療,但卻容易令耳朵產生的分泌物會形成菌膜,阻塞導管,甚至造成反覆感染。中文大學跨學科研究團隊合作,研發「磁控螺旋微機械人」系統,以螺旋形微型機械人為基礎,結合機械臂輔助的磁控遙距驅動及內窺鏡遞送和觀察,清除中耳導管的菌膜,可以無痛、無損的方式進行治療。

Date: 
Thursday, October 27, 2022
Media: 
HKET Daily

中大研外牆檢測機械人 取代吊船作業減風險

近期本港接連發生多宗工業意外,通過科技可避免風險。中文大學機械與自動化工程學系研發線控機械人,可取代傳統乘搭吊船的人手檢測大廈外牆,機械人會就外牆安全程度製作圖像,讓承建商了解不同部分的安全風險。中大亦研發「交易及風險管理深度學習模型」,運用數據與人工智能,僅零點零三秒得出買賣決定,兩者連同逾二十項研究項目,將於本月起舉行的多個科技展覽中公開展出。
 
Date: 
Friday, October 7, 2022
Media: 
Sing Tao Daily

CUHK researchers develop novel RNA nanoparticles for targeting and alleviating atherosclerotic plaque

Date: 
2022-10-07
Thumbnail: 
Body: 
The blockage of blood vessels caused by atherosclerosis is a major cause of stroke and ischemic heart disease. However, current treatments such as surgery are invasive, while lipid-lowering drugs can only slow down disease progression. Gene regulation is an emerging therapeutic approach to atherosclerosis, but delivery of therapeutic gene cargoes to atherosclerotic plaques is still inefficient. A team led by Professor Jonathan Choi Chung-hang, Associate Professor in the Faculty of Engineering’s Department of Biomedical Engineering, has developed a novel RNA nanoparticle to offer a potentially safe, effective treatment for atherosclerosis.
 
Research has shown that this RNA nanoparticle can naturally target receptors of plaque cells for delivering genes to atherosclerotic plaques, while alleviating atherosclerosis by modulating genes related to atherogenesis, consequently reducing and stabilising plaque without inducing severe toxicity. It paves the way for the use of nucleic acid nanotechnology to treat cardiovascular diseases. This research, a collaboration with Professor Tian Xiao-yu, Assistant Professor in the Faculty of Medicine’s School of Biomedical Sciences at CUHK, has recently been published in the international journal The Proceedings of the National Academy of Sciences (PNAS).
 
Limitations of existing treatments
 
Atherosclerosis is a form of chronic inflammation, mainly induced by high levels of blood lipids. The buildup of fats, cholesterol and immune cells on the arterial wall will cause the formation of atherosclerotic plaques. Such plaques can either narrow the blood vessels to restrict the flow of blood or burst to form blood clots that block thinner arteries in the brain or heart, leading to stroke or ischemic heart disease. According to the World Health Organisation (WHO), stroke and ischemic heart disease accounted for 11% and 16% respectively of global mortality in 2020. In Hong Kong, heart disease has been the third-leading cause of death since the 1960s.
 
Existing treatments for atherosclerosis include surgical procedures such as balloon angioplasty and endarterectomy, but they are invasive and inefficient in reducing multiple plaque sites. Another treatment is administration of lipid-lowering drugs such as statins, but they can only slow down disease progression.
 
Bypassing the bottleneck for gene delivery with nucleic acid nanotechnology
 
Gene regulation is an emerging therapeutic approach to atherosclerosis, but current technology for gene delivery to plaque remains inefficient. Existing atherosclerosis nanomedicines mostly employ cationic carriers to complex gene cargoes through electrostatic interactions for gene delivery into plaque cells. Yet, these nanomedicines are often bulky, larger than 100 nm, meaning they can be rapidly filtered by the liver and spleen following an intravenous injection before they reach the plaque; and they are cationic which may induce cytotoxicity in the body.
 
Bypassing this bottleneck in gene delivery, Professor Choi’s team has applied nucleic acid nanotechnology to develop a new RNA nanoparticle for plaque delivery. This smaller spherical nanoparticle of about 70 nm in size includes a biocompatible iron oxide nanoparticle core, and about 300 therapeutic microRNA-146a strands attached to the core’s surface. It can naturally enter plaque cells without the aid of cationic transfection agents, thereby facilitating the intracellular delivery of microRNA-146a.
 
Data from the experiments have shown that upon an intravenous injection into mice that bear atherosclerotic plaques, the new RNA nanoparticle can naturally target the receptors on plaque cells and preferentially enter macrophages and endothelial cells inside the plaque. Dr Shirley Bai Qian-qian, first author of the publication and PhD graduate in the Faculty of Engineering’s Department of Biomedical Engineering, added, “The unique receptor-targeting property of the RNA nanoparticles contributes to their elevated plaque accumulation of up to 1.2% of the injected dose, one of the highest in the field of nanomedicine.”
 
Alleviating atherosclerosis with intravenous injections of RNA nanostructures
 
Furthermore, experiments have shown that repeated injections of RNA nanoparticles into plaque-bearing mouse models not only regressed and stabilised atherosclerotic plaque, but also downregulated genes related to immune response and vascular inflammation. After four weeks of treatment, there was no pronounced accumulation of RNA nanoparticle inside major internal organs, nor did it induce severe toxicity.
 
Professor Choi added, “This study highlights the promise of nucleic acid nanotechnology to treat cardiovascular diseases. We hope to continue our collaboration with the CUHK Faculty of Medicine by validating the safety and efficacy of this RNA nanostructure in large animals. Ultimately, we hope to offer a safe, effective nanomedicine for patients with cardiovascular disease.”
 
The project was supported by the Research Grants Council of Hong Kong, the CUHK Vice-Chancellor Discretionary Fund, the CUHK Chow Yuk Ho Technology Centre for Innovative Medicine, the National Nature Science Foundation of China, and the Croucher Innovation Award from the Croucher Foundation.
 
The research paper can be found at https://www.pnas.org/doi/10.1073/pnas.2201443119.
 
(extracted from the press release issued on 5 Oct 2022 by CUHK Communications and Public Relations Office)

(From left) Dr Shirley Bai Qian-qian, first author of the publication and PhD graduate in the Faculty of Engineering’s Department of Biomedical Engineering, and her two thesis supervisors: Professor Jonathan Choi Chung-hang, Associate Professor in the Faculty of Engineering’s Department of Biomedical Engineering, and Professor Tian Xiao-yu, Assistant Professor in the Faculty of Medicine’s School of Biomedical Sciences.

The novel RNA nanoparticles are placed in a aqueous solution.

The outer microRNA shell promotes the delivery of nanoparticles to the plaque upon intravenous injection into mice with atherosclerosis.

The spherical RNA nanoparticle contains a poly (ethylene glycol)-coated iron oxide nanoparticle inner core and an outer three-dimensional shell of microRNA-146a oligonucleotides. Upon intravenous injection, the RNA nanoparticle can accumulate in the atherosclerotic plaque and enter macrophages and endothelial cells inside the plaque.

Repeated intravenous injections of RNA nanoparticles into mice with atherosclerosis reduced the atherosclerotic plaque area in the aorta by about 30%.

 

Filter: Dept: 
Faculty
BME
Media Release

直遞基因藥到動脈斑塊減形成 新納米顆粒助治心血管病

心血管疾病能殺人於無形,惟通波仔等針對動脈粥樣硬化治療多具入侵性,納米藥物亦有機會引發體內細胞毒性。中大工程學院與醫學院團隊聯手研發新型核糖核酸(RNA)納米顆粒,除可協助基因藥「直擊」動脈粥樣斑塊,亦可穩定及減少斑塊形成;動物實驗證明顆粒不會在主要內臟大量積聚,亦未引起嚴重毒性,未來有望提升治療中風、缺血性心臟病等效益。

Date: 
Thursday, October 6, 2022
Media: 
晴報

中大研納米顆粒 抑血管脂肪結塊

「動脈粥樣硬化」患者的血管內壁會累積脂肪斑塊,導致血管變窄、阻塞血流,誘發中風或缺血性心臟病。據世衛數據,這兩類疾病前年的全球死亡率分別達11%和16%,惟「通波仔」等常見治療手法具侵入性,部分藥物則只能減慢病情惡化。中大工程學院生物醫學工程學系團隊研發一款新型核糖核酸(RNA)納米顆粒,能自主進入斑塊細胞,穩定及減少斑塊形成

Date: 
Thursday, October 6, 2022
Media: 
MingPao Daily

中大研新型納米顆粒 自發進入斑塊細胞 有效醫治心血管病

動脈粥樣硬化主要由高血脂水平誘發,會導致血管阻塞,繼而引發中風和缺血性心臟病。香港中文大學工程學院生物醫學工程學系團隊,研發出一款新型核糖核酸(RNA)納米顆粒,這種顆粒能自發進入動脈粥樣硬化斑塊細胞的受體,調控與斑塊形成相關基因,在安全情況下減少及穩定斑塊。

Date: 
Thursday, October 6, 2022
Media: 
On.CC
Name: 
YUE Xiangyu
Title ( post ): 
Assistant Professor
Department: 
Information Engineering
email: 
xyyue [at] ie.cuhk.edu.hk
phone: 
3943-8357
website: 
https://www.ie.cuhk.edu.hk/people/xyyue.shtml
Avatar: 
Class: 
faculty_member
Chinese Name: 
岳翔宇
glossary_index: 
Y

Professor Anthony So awarded 2022 UGC Teaching Award

Date: 
2022-09-26
Thumbnail: 
Body: 
Professor Anthony Man-cho So, Professor of Department of Systems Engineering and Engineering Management, has been awarded the 2022 UGC Teaching Award (General Faculty Members) by the University Grants Committee, in recognition of his achievements in learner-centred teaching and leadership in multidisciplinary curriculum and programme design.
 
Professor So said he was very honoured to win this distinguished award, commenting, “It is my strong belief that every student has his or her potential, and my mission as a teacher is to help students discover and unleash their talents. This award recognises my team’s hard work and reaffirms our dedication to teaching. I would like to thank all my colleagues and students at CUHK for their unconditional support. They are my constant source of inspiration and strength.”
 
Professor Anthony So joined CUHK in 2007. He is currently Dean of the Graduate School, Deputy Master of Morningside College and Professor of the Department of Systems Engineering and Engineering Management. His excellence in teaching has earned him multiple accolades, including the University Education Award 2022, the Vice Chancellor’s Exemplary Teaching Award 2013, and the Dean’s Exemplary Teaching Award for three times (2011, 2013 and 2015).
 
Professor So’s teaching philosophy is learner-centred. He adopts a Think-Act-Communicate-Test and Investigate-Connect (TACTIC) approach, which not only focuses on training students’ technical skills but also emphasises an interdisciplinary learning perspective. Professor So is keen on connecting the dots between engineering and the humanities in his teaching. Since 2019, he has delivered lectures on ethical dilemmas in artificial intelligence as part of a college-wide general education course.
 
Over the years, Professor So has spearheaded efforts in curriculum enhancement and building a collaborative learning community among teachers to address students’ real needs. He was tapped to lead the faculty’s ELITE (Engineering, Leadership, Innovation, Technology and Entrepreneurship) Stream, which aims to nurture outstanding engineering students and to develop their potentials through additional challenging coursework and invaluable extracurricular activities. He also initiated and led a faculty-wide revamp of the engineering mathematics curriculum. The six new courses were launched in 2019-20.
 
Breaking new ground in engineering education, Professor So introduced the first-of-its-kind writing component to CUHK’s engineering courses and has provided students with much-needed training on technical writing. To deepen this initiative, he plans to use the award to develop a course titled “Mathematical Writing for Engineers”, which equips students at various levels with practical research paper writing skills. With the wide range of applications of technical writing in different disciplines, it is envisioned that the course will also benefit students from non-engineering fields, creating a far-reaching impact on teaching and learning.
 

(extracted from the press release issued on 26 Sep 2022 by CUHK Communications and Public Relations Office).

 

Professor Anthony So (left) receives the award certificate from Mr Carlson Tong, Chairman of UGC.

Professor Anthony So delivers his acceptance speech

 

Filter: Dept: 
Faculty
SEEM
Media Release

Pages